|
|
|
|
| LEADER |
01804 am a22002773u 4500 |
| 001 |
110374 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Bersini, S.
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Mechanical Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Jeon, Jessie S
|e contributor
|
| 100 |
1 |
0 |
|a Kamm, Roger Dale
|e contributor
|
| 700 |
1 |
0 |
|a Moretti, Matteo
|e author
|
| 700 |
1 |
0 |
|a Jeon, Jessie S
|e author
|
| 700 |
1 |
0 |
|a Kamm, Roger Dale
|e author
|
| 245 |
0 |
0 |
|a In vitro models of the metastatic cascade: from local invasion to extravasation
|
| 260 |
|
|
|b Elsevier,
|c 2017-06-29T17:46:33Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/110374
|
| 520 |
|
|
|a A crucial event in the metastatic cascade is the extravasation of circulating cancer cells from blood capillaries to the surrounding tissues. The past 5 years have been characterized by a significant evolution in the development of in vitro extravasation models, which moved from traditional transmigration chambers to more sophisticated microfluidic devices, enabling the study of complex cell-cell and cell-matrix interactions in multicellular, controlled environments. These advanced assays could be applied to screen easily and rapidly a broad spectrum of molecules inhibiting cancer cell endothelial adhesion and extravasation, thus contributing to the design of more focused in vivo tests.
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (R33 CA174550-01)
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (R21 CA140096)
|
| 520 |
|
|
|a Repligen Corporation (Repligen Fellowship in Cancer Research)
|
| 520 |
|
|
|a Charles Stark Draper Laboratory (Draper Fellowship)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Drug Discovery Today
|
